Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Chlordiazepoxide

FDA-approved product (capsule, extended release, oral), marketed as Librelease, Libritabs, A-Poxide and 4 more.

Registered studies
8
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Chlordiazepoxide
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Alcohol dependence
  • Anxiety
  • Anxiety disorder

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Benzodiazepine derivatives
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA51.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli30.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae8.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis63.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

8registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Chlordiazepoxide in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-6.6 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.3 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-6.0 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.5 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Chlordiazepoxide with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Stellate Ganglion Block Versus Oral Medication in Treatment of Palmar Hyperhidrosis

    NCT06731101 · start 2025-01-15

    Registered record
    Registry ID
    NCT06731101
    Conditions
    Palmar Hyperhidrosis
    Interventions
    Bupivacaine + Lidocaine +dexamethasone; Tryptizole + Librax
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2025-01-15
    Completion
    2026-01-01
    Enrolment
    46

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPalmar Hyperhidrosis
    InterventionBupivacaine + Lidocaine +dexamethasone; Tryptizole + Librax
    PhaseNot applicable
    Registry statusCompleted

  • Metabolism of Chlordiazepoxide in the Treatment of Alcohol Withdrawal Symptoms

    NCT05563350 · start 2022-01-29

    Registered record
    Registry ID
    NCT05563350
    Conditions
    Alcohol Withdrawal
    Interventions
    Blood samples
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2022-01-29
    Completion
    2023-07-01
    Enrolment
    26

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAlcohol Withdrawal
    InterventionBlood samples
    PhaseNot recorded
    Registry statusCompleted

  • Gabapentin for Alcohol Withdrawal Syndrome

    NCT03012815 · start 2017-02-01

    Registered record
    Registry ID
    NCT03012815
    Conditions
    Alcohol Withdrawal Syndrome
    Interventions
    Gabapentin; Benzodiazepines; Divalproex Sodium
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2017-02-01
    Completion
    2021-03-01
    Enrolment
    88

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAlcohol Withdrawal Syndrome
    InterventionGabapentin; Benzodiazepines; Divalproex Sodium
    PhasePhase 4
    Registry statusCompleted

  • Treatment of Alcohol Withdrawal Syndrome With Alpha-2 Agonists and/or Anticonvulsants

    NCT05438641 · start 2013-08

    Registered record
    Registry ID
    NCT05438641
    Conditions
    Alcohol Withdrawal Syndrome
    Interventions
    BZDP-Sparing Protocol; BZDP-Based Protocol
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2013-08
    Completion
    2017-08
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAlcohol Withdrawal Syndrome
    InterventionBZDP-Sparing Protocol; BZDP-Based Protocol
    PhaseNot recorded
    Registry statusCompleted

  • Pioglitazone as an Adjunct for Moderate to Severe Depressive Disorder

    NCT01109030 · start 2010-04

    Registered record
    Registry ID
    NCT01109030
    Conditions
    Major Depressive Disorder
    Interventions
    Pioglitazone+Citalopram+Chlordiazepoxide; Placebo+ Citalopram+ Chlordiazepoxide
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2010-04
    Completion
    2011-10
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMajor Depressive Disorder
    InterventionPioglitazone+Citalopram+Chlordiazepoxide; Placebo+ Citalopram+ Chlordiazepoxide
    PhasePhase 2 / Phase 3
    Registry statusCompleted

  • Gabapentin vs Chlordiazepoxide for Ambulatory Alcohol Withdrawal

    NCT01573052 · start 2004-03

    Registered record
    Registry ID
    NCT01573052
    Conditions
    Alcohol Withdrawal
    Interventions
    Chlordiazepoxide; Gabapentin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2004-03
    Completion
    2010-09
    Enrolment
    26

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAlcohol Withdrawal
    InterventionChlordiazepoxide; Gabapentin
    PhasePhase 4
    Registry statusCompleted

  • Outpatient Treatment of Alcohol Withdrawal Syndrome

    NCT00136617 · start 2003-08

    Registered record
    Registry ID
    NCT00136617
    Conditions
    Alcoholism; Alcohol Withdrawal
    Interventions
    chlordiazepoxide
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2003-08
    Completion
    2008-09
    Enrolment
    165

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAlcoholism; Alcohol Withdrawal
    Interventionchlordiazepoxide
    PhasePhase 3
    Registry statusCompleted

  • A Study of the Use of Combination of Anti-cholinergic and Minor Tranquilliser in the Treatment of Non-cardiac Chest Pain - a Double Blind Placebo Controlled Study

    NCT00516854 · start 2002-06

    Registered record
    Registry ID
    NCT00516854
    Conditions
    Chest Pain
    Interventions
    chlordiazepoxide 5 mg, clidinium 2.5 mg, twice daily
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2002-06
    Completion
    2008-12
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChest Pain
    Interventionchlordiazepoxide 5 mg, clidinium 2.5 mg, twice daily
    PhaseNot applicable
    Registry statusUnknown